Yeast spotlights genetic variation’s link to drug resistance

Study shows that genetic diversity influences which adaptive mutations cause antimicrobial resistance

Yeast spotlights genetic variation’s link to drug resistance

Genetic diversity can prime a cell population to acquire antimicrobial resistance. The researchers showed that pre-existing and de novo genetic variation both contribute to resistance evolution.

Researchers have shown that genetic diversity plays a key role in enabling drug resistance to evolve. Scientists at the Wellcome Trust Sanger Institute and the Institute for Research on Cancer and Ageing of Nice in France show that high genetic diversity can prime new mutations that cause drug resistance. The study published today (17 October) in Cell Reports has implications for our understanding of the evolution of resistance to antimicrobial and anticancer drugs.

The World Health Organisation classes antimicrobial resistance as one of the biggest threats to global health today. Currently 700,000 deaths a year worldwide*, with 25,000 of those in the EU and 23,000 in the USA are linked to antimicrobial resistance. These figures are projected** to rise to 10 million deaths a year by 2050 if nothing is done to tackle the problem. Equally, cancer is linked to 8.2 million annual deaths worldwide, with chemotherapy resistance a major limitation to treatment.

Previous studies had linked high genetic diversity within bacterial infections or in cancers with poor outcomes for patients treated with antimicrobial or chemotherapy drugs. Researchers in this study used budding yeast, creating populations of cells with more than 10 million different randomised genomes, to investigate how genetic diversity affected resistance. They evolved these to grow in antimicrobial drugs over four weeks and then studied the sensitive and resistant yeast cells.

"We found that the degree of diversity within the cell population – known as clonal heterogeneity – played a major role in the acquisition of antimicrobial resistance. By sequencing the genomes of sensitive and resistant cells we showed that some cells were pre-adapted, or primed, while other cells acquired new mutations to gain resistance.”

Dr Ignacio Vazquez-Garcia, the first author from the Wellcome Trust Sanger Institute and University of Cambridge

By then crossing the evolved strains, the researchers were able to investigate the complex evolutionary processes involved in developing resistance. They were able to see not only which mutations drove resistance – called driver mutations – but also how the background mutations affected these.

They discovered two types of driver mutations. Cells with weak driver mutations needed other background mutations to grow well in antimicrobial drugs, however cells with strong driver mutations developed resistance to drugs regardless of the genetic background.

“We were able to study the evolution in time by combining genome sequences of the cell populations and tracking the growth characteristics of the yeast cells. We found that the genetic background had a major influence on whether or not weaker mutations would confer drug resistance, and in these cases many different cells adapted in a wave. However, with any genetic background, cells with strong driver mutations could “leapfrog” and outcompete other cells growing in the drugs.”

Professor Gianni Liti, a senior author on the paper from the Institute for Research on Cancer and Ageing, Nice

“Our study helps understand the evolution of drug resistance, and has implications not just for yeast, but also for bacteria and cancer. Whilst further study is needed, we are building evidence to show that genetic diversity in a bacterial infection or in a tumour being treated could lay the foundation for resistance to the therapy and affect how quickly resistance develops.”

Professor Ville Mustonen, Senior author from the University of Helsinki and previously at the Wellcome Trust Sanger Institute

Notes to Editors
  • Clonal Heterogeneity Influences the Fate of New Adaptive Mutations.

    Vázquez-García I, Salinas F, Li J, Fischer A, Barré B et al.

    Cell reports 2017;21;3;732-744

* These figures on antimicrobial resistance have been released by the CDC ( and as part of a joint report** by the UK Government and the Wellcome Trust (

Further figures on cancer management are available from the International Agency for Research on Cancer of the World Health Organisation (


This work was supported by the Wellcome Trust, Fundación Ibercaja, Fondation ARC, the French National Research Agency, Cancéropôle PACA, DuPont and other funding organisations. Please see the paper for the full list of funders.

Participating Centres:
  • Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK
  • Department of Applied Mathematics and Theoretical Physics, Centre for Mathematical Sciences, University of Cambridge, Cambridge, UK
  • Université Côte d’Azur, Institute for Research on Cancer and Ageing of Nice, CNRS UMR 7284, INSERM U1081, Nice, France
  • Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden
  • Centre for Integrative Genetics, Department of Animal and Aquacultural Sciences, Norwegian University of Life Sciences, Ås, Norway

Selected Websites
Using yeast in biologyStoriesUsing yeast in biology
Yeast is one of the simplest eukaryotic organisms but many essential cellular processes are the same in yeast and humans. It is therefore an important organism to study to understand basic molecular processes in humans.

Why use yeast in research?FactsWhy use yeast in research?
Baker’s yeast, or Saccharomyces cerevisiae as it is also known, is among the best-studied experimental organisms.

What are model organisms?FactsWhat are model organisms?
A model organism is a species that has been widely studied, usually because it is easy to maintain and breed in a laboratory setting and has particular experimental advantages.

Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
CB10 1SA,

Mobile +44 (0) 7748 379849

Recent News

From childhood cancer to mapping human development: Pioneering scientist awarded 2019 Foulkes Foundation medal
Congratulations to Professor Muzlifah Haniffa, who has been recognised for her work on the immune system and childhood cancer
Dr Sam Behjati wins Liddy Shriver Early Career Research Award
Congratulations to Sanger Institute cancer researcher, Dr Sam Behjati, who has been recognised for his work in sarcoma cancer genomics
New malaria drug targets identified in liver stage of life cycle
Hope that new liver-stage drugs will help to counter the threat of antimicrobial resistance to current blood-stage medicines